The estimated Net Worth of Laura Brege is at least $1.01 Million dollars as of 16 August 2024. Ms. Brege owns over 1,000 units of Pacira BioSciences Inc stock worth over $228,176 and over the last 17 years she sold PCRX stock worth over $331,329. In addition, she makes $445,946 as Independent Director at Pacira BioSciences Inc.
Laura has made over 23 trades of the Pacira BioSciences Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently she bought 1,000 units of PCRX stock worth $12,810 on 16 August 2024.
The largest trade she's ever made was exercising 46,153 units of Pacira BioSciences Inc stock on 10 September 2013 worth over $59,999. On average, Laura trades about 3,324 units every 48 days since 2008. As of 16 August 2024 she still owns at least 17,552 units of Pacira BioSciences Inc stock.
You can see the complete history of Ms. Brege stock trades at the bottom of the page.
Laura A. Brege serves as Independent Director of the Company. Since April 2018, Ms. Brege has served as Senior Advisor to BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases. From September 2015 to June 2018, Ms. Brege served as Managing Director of Cervantes Life Science Partners, LLC., a health care advisory and consulting company. From September 2012 to July 2015, Ms. Brege served as President and Chief Executive Officer of Nodality, Inc., a privately held biotechnology company focused on oncology and immunology. Previously, Ms. Brege held the roles of Chief Operating Officer, Executive Vice President, Chief Business Officer and Head of Corporate Affairs at Onyx Pharmaceuticals, Inc. ("Onyx"), a biopharmaceutical company that developed and marketed medicines for the treatment of cancer. Prior to joining Onyx in 2006, Ms. Brege was a General Partner at Red Rock Capital Management, a venture capital firm, and Senior Vice President and Chief Financial Officer at COR Therapeutics, Inc. Ms. Brege currently serves as a director of Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), HLS Therapeutics, Inc. (TSX: HLS), Portola Pharmaceuticals, Inc. (Nasdaq: PTLA) and Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM). She previously served as a member of the board of directors of Aratana Therapeutics, Inc. (Nasdaq: PETX) from February 2014 until March 2019 and Dynavax Technologies Corporation (Nasdaq: DVAX) from 2015 to 2020. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago.
As the Independent Director of Pacira BioSciences Inc, the total compensation of Laura Brege at Pacira BioSciences Inc is $445,946. There are 14 executives at Pacira BioSciences Inc getting paid more, with David Stack having the highest compensation of $5,806,430.
Laura Brege is 62, she's been the Independent Director of Pacira BioSciences Inc since 2011. There are 4 older and 21 younger executives at Pacira BioSciences Inc. The oldest executive at Pacira BioSciences Inc is Gary Pace, 72, who is the Independent Director.
Laura's mailing address filed with the SEC is C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA, FL, 33609.
Over the last 14 years, insiders at Pacira BioSciences Inc have traded over $321,391,130 worth of Pacira BioSciences Inc stock and bought 2,075,444 units worth $15,133,188 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Carl L Gordon und Andreas Wicki. On average, Pacira BioSciences Inc executives and independent directors trade stock every 13 days with the average trade being worth of $491,036. The most recent stock trade was executed by Marcelo Bigal on 16 August 2024, trading 1,512 units of PCRX stock currently worth $20,034.
pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
Pacira BioSciences Inc executives and other stock owners filed with the SEC include: